US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

0.5794

-0.0088-1.50%

Post-market: 0.57990.0005+0.09%16:47 EDT

Volume:38.76K

Turnover:22.52K

Market Cap:12.06M

PE:-1.90

High:0.6000

Open:0.5703

Low:0.5700

Close:0.5882

52wk High:2.11

52wk Low:0.4000

Shares:20.82M

Float Shares:1.55M

Volume Ratio:0.32

T/O Rate:2.50%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3056

EPS(LYR):-0.2292

ROE:-92.07%

ROA:-53.59%

PB:1.57

PE(LYR):-2.53

Loading ...

Overview Company News Filings

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT)

Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy

Kairos Pharma Signs Binding Deal to Acquire Worldwide Rights to CL-273

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to Cl-273 From Orbimed and Torrey Pines Investment-Backed Celyn Therapeutics

THOMSON REUTERS

Kairos Pharma Ltd - to Buy Cl-273 From Celyn Therapeutics

THOMSON REUTERS

BRIEF-Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition

Kairos Pharma signs term sheet to acquire CL-273 and CL-741 from Celyn Therapeutics

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets From Celyn Therapeutics

THOMSON REUTERS

Kairos Pharma Ltd - to Buy Rights to Cl-273 and Cl-741

THOMSON REUTERS

Kairos Pharma to Present at DealFlow Discovery Conference in Atlantic City

Kairos Pharma Ltd - May Offer up to $75 Mln in Securities - SEC Filing

THOMSON REUTERS

Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Secures Department of Defense Funding for ENV205 Cancer Drug Research

Kairos Pharma Provides Shareholder Update

THOMSON REUTERS

Kairos Pharma Is Maintained at Buy by D. Boral Capital

Kairos Pharma Reports Positive Phase 2 Results for ENV-105 in Advanced Prostate Cancer

Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":0.5794,"timestamp":1774641600000,"preClose":0.5882,"halted":0,"volume":38760,"hourTrading":{"tag":"盘后","latestPrice":0.5799,"preClose":0.5794,"latestTime":"16:47 EDT","volume":102,"amount":59.1494,"timestamp":1774644423812,"change":0.0005,"changeRate":0.000863,"amplitude":0.000863},"delay":0,"changeRate":-0.014960897653859094,"floatShares":1550000,"shares":20821353,"eps":-0.30563,"marketStatus":"Market Closed","change":-0.0088,"latestTime":"03-27 16:00:00 EDT","open":0.5703,"high":0.6,"low":0.57,"amount":22517.97084,"amplitude":0.051003,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.30563,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1717992000000,"exchange":"AMEX","adjPreClose":0.5882,"preHourTrading":{"tag":"盘前","latestPrice":0.5888,"preClose":0.5882,"latestTime":"09:28 EDT","volume":990,"amount":573.0359184,"timestamp":1774618120145,"change":0.0006,"changeRate":0.00102,"amplitude":0.084835},"postHourTrading":{"tag":"盘后","latestPrice":0.5799,"preClose":0.5794,"latestTime":"16:47 EDT","volume":102,"amount":59.1494,"timestamp":1774644423812,"change":0.0005,"changeRate":0.000863,"amplitude":0.000863},"volumeRatio":0.31859211551918093},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":1550000,"roa":"-53.59%","roe":"-92.07%","lyrEps":-0.229208,"volumeRatio":0.31859211551918093,"shares":20821353,"dividePrice":0,"high":0.6,"amplitude":0.051003,"preClose":0.5882,"low":0.57,"week52Low":0.4,"pbRate":"1.57","week52High":2.11,"institutionHeld":0,"latestPrice":0.5794,"eps":-0.30563,"divideRate":0,"volume":38760,"delay":0,"ttmEps":-0.30563,"open":0.5703,"prevYearClose":0.71,"prevWeekClose":0.5995,"prevMonthClose":0.6055,"prevQuarterClose":0.71,"fiveDayClose":0.5995,"twentyDayClose":0.6055,"sixtyDayClose":0.6998},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2026-03-27","current":-1.895756,"percent":0.971279,"low":-25.607053,"twenty":-7.358428,"median":-4.925987,"eighty":-2.995692,"high":-2.140651,"avg":-5.42751,"sd":2.929759,"marketCap":12247119},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-18","current":-4.852143,"twenty":-8.578362,"median":-6.210138,"eighty":-4.078861,"marketCap":17186292},{"date":"2025-07-25","current":-4.424013,"twenty":-8.501541,"median":-6.156578,"eighty":-4.315248,"marketCap":15669854},{"date":"2025-08-01","current":-4.281779,"twenty":-8.456729,"median":-5.830571,"eighty":-4.144691,"marketCap":15166060},{"date":"2025-08-08","current":-4.566723,"twenty":-8.326712,"median":-5.698056,"eighty":-4.256377,"marketCap":16175333},{"date":"2025-08-15","current":-5.460044,"twenty":-8.265781,"median":-5.577408,"eighty":-4.144691,"marketCap":25722268},{"date":"2025-08-22","current":-5.151816,"twenty":-8.175816,"median":-5.56016,"eighty":-4.256377,"marketCap":24270205},{"date":"2025-08-29","current":-5.548109,"twenty":-8.117706,"median":-5.504045,"eighty":-4.350727,"marketCap":26137143},{"date":"2025-09-05","current":-6.825055,"twenty":-8.080211,"median":-5.554134,"eighty":-4.371339,"marketCap":32152835},{"date":"2025-09-12","current":-7.925871,"twenty":-8.146034,"median":-5.577408,"eighty":-4.403843,"marketCap":37338777},{"date":"2025-09-19","current":-5.90037,"twenty":-8.123413,"median":-5.684601,"eighty":-4.424013,"marketCap":27796645},{"date":"2025-09-26","current":-5.019718,"twenty":-8.080211,"median":-5.577408,"eighty":-4.452555,"marketCap":23647892},{"date":"2025-10-03","current":-5.063751,"twenty":-8.031527,"median":-5.554134,"eighty":-4.485854,"marketCap":23855329},{"date":"2025-10-10","current":-5.812305,"twenty":-7.985263,"median":-5.56016,"eighty":-4.525921,"marketCap":27381769},{"date":"2025-10-17","current":-5.151816,"twenty":-7.967725,"median":-5.531688,"eighty":-4.55855,"marketCap":24270205},{"date":"2025-10-24","current":-4.799555,"twenty":-7.967725,"median":-5.492822,"eighty":-4.58125,"marketCap":22610703},{"date":"2025-10-31","current":-5.019718,"twenty":-7.967725,"median":-5.46521,"eighty":-4.595432,"marketCap":23647892},{"date":"2025-11-07","current":-3.830837,"twenty":-7.967725,"median":-5.399832,"eighty":-4.525921,"marketCap":18047075},{"date":"2025-11-14","current":-3.48298,"twenty":-7.942613,"median":-5.371979,"eighty":-4.424013,"marketCap":16408318},{"date":"2025-11-21","current":-2.82458,"twenty":-7.922862,"median":-5.327946,"eighty":-4.230974,"marketCap":14298023},{"date":"2025-11-28","current":-3.42923,"twenty":-7.902108,"median":-5.296194,"eighty":-4.097795,"marketCap":17358761},{"date":"2025-12-05","current":-3.740193,"twenty":-7.855239,"median":-5.283914,"eighty":-3.903739,"marketCap":18932856},{"date":"2025-12-12","current":-3.331745,"twenty":-7.817744,"median":-5.203591,"eighty":-3.780288,"marketCap":16865295},{"date":"2025-12-19","current":-3.187781,"twenty":-7.79431,"median":-5.197038,"eighty":-3.655562,"marketCap":16136548},{"date":"2025-12-26","current":-3.052866,"twenty":-7.780249,"median":-5.190491,"eighty":-3.531486,"marketCap":15453608},{"date":"2026-01-02","current":-2.920419,"twenty":-7.780249,"median":-5.153702,"eighty":-3.48298,"marketCap":14783160},{"date":"2026-01-09","current":-3.989868,"twenty":-7.780249,"median":-5.151816,"eighty":-3.42923,"marketCap":20196712},{"date":"2026-01-16","current":-3.660807,"twenty":-7.780249,"median":-5.14469,"eighty":-3.42923,"marketCap":18531004},{"date":"2026-01-23","current":-3.208347,"twenty":-7.755842,"median":-5.119133,"eighty":-3.42923,"marketCap":16240655},{"date":"2026-01-30","current":-2.734499,"twenty":-7.661662,"median":-5.098261,"eighty":-3.381278,"marketCap":13842035},{"date":"2026-02-06","current":-2.426827,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"marketCap":12284598},{"date":"2026-02-13","current":-2.442869,"twenty":-7.51395,"median":-5.063751,"eighty":-3.27767,"marketCap":12365801},{"date":"2026-02-20","current":-2.303429,"twenty":-7.470914,"median":-5.048278,"eighty":-3.204892,"marketCap":11659957},{"date":"2026-02-27","current":-2.271757,"twenty":-7.452166,"median":-5.027001,"eighty":-3.156747,"marketCap":11499633},{"date":"2026-03-06","current":-2.698302,"twenty":-7.424045,"median":-5.019718,"eighty":-3.093003,"marketCap":13658807},{"date":"2026-03-13","current":-2.46796,"twenty":-7.400606,"median":-4.98699,"eighty":-3.049512,"marketCap":12492811},{"date":"2026-03-20","current":-2.529659,"twenty":-7.374048,"median":-4.948312,"eighty":-3.027281,"marketCap":12805132},{"date":"2026-03-27","current":-2.419423,"twenty":-7.358428,"median":-4.925987,"eighty":-2.995692,"marketCap":12247119}],"updateTime":1774780222454},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618949521","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Kairos Pharma, Ltd. (KAPA), Pfizer (PFE) and Medtronic (MDT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618949521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618949521?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:00","pubTimestamp":1773226813,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kairos Pharma, Ltd. (KAPA – Research Report), Pfizer (PFE – Resea...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kairos-pharma-ltd-kapa-pfizer-pfe-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-kairos-pharma-ltd-kapa-pfizer-pfe-and-medtronic-mdt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1894683264.USD","LU0265550359.USD","LU0976567544.SGD","LU0306806265.USD","LU0496365809.HKD","IE00BQXX3C00.GBP","LU1116320737.USD","LU1989771016.USD","LU2028103732.USD","LU0289739699.SGD","LU0058720904.USD","IE00BQXX3D17.EUR","IE00B19Z3581.USD","SGXZ57979304.SGD","BK4007","XBI","LU0208291251.USD","LU2089284900.SGD","LU1989764664.SGD","LU0158827781.USD","LU2468319806.SGD","LU2089984988.USD","LU0234572021.USD","LU0072461881.USD","IE00BVYPNW00.USD","LU0070302665.USD","IE00B3PB1722.GBP","LU1061106388.HKD","BK4534","LU1894683348.USD","MDT","SG9999001176.USD","LU0211331839.USD","LU0265550946.USD","LU0162691827.USD","BK4581","IE00BVYPNV92.GBP","BK4550","LU0314106906.USD","IE00BGHQF631.EUR","LU1571399168.USD","LU0321505868.SGD","IE00B3T34201.USD","LU0321505439.SGD","LU0122379950.USD","IE00BBT3K403.USD","LU1244550494.USD","LU0029874061.USD","IE00BFXG1179.USD","LU0225771236.USD","IE00B19Z3B42.SGD","BK4566","BK4585","BK4082","LU1116320901.HKD","LU0158827948.USD","LU1066051498.USD","IE00BLSP4239.USD","PFE","BK4599","LU2023251221.USD","LU0320765489.SGD","LU1983299246.USD","LU0170899867.USD","SG9999013999.USD","IE00BQXX3F31.USD","LU1244550221.USD","SG9999011175.SGD","LU1291159041.SGD","LU0306807586.USD","LU0868494617.USD","BK4137","LU1066053197.SGD","LU1023059063.AUD","LU2111349929.HKD","IE00BLSP4452.SGD","LU2271345857.HKD","SG9999002232.USD","LU1989764748.USD","BK4588","LU0128526141.USD","IE0002270589.USD","LU0225284248.USD","LU1057294990.SGD","BK4568","LU1244550577.SGD","LU0985481810.HKD","BK4139","SG9999002224.SGD","LU0432979614.USD","BK4533","IE00BDGV0183.EUR","LU0211326839.USD","LU1883839398.USD","LU2089283258.USD","SG9999003800.SGD","LU0211326755.USD","IE000M9KFDE8.USD","SG9999001176.SGD","LU2112291526.USD","BK4592","IE00B42XCP33.USD","LABU","LU1506573853.SGD","LU0456855351.SGD","KAPA"],"gpt_icon":0},{"id":"2616331039","title":"Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331039","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331039?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:19","pubTimestamp":1772453953,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On March 2, 2026, Kairos Pharma, Ltd. entered into a binding term sheet to acquire from...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-acquires-rights-to-ai-discovered-egfr-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-acquires-rights-to-ai-discovered-egfr-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA","BK4139"],"gpt_icon":0},{"id":"2616433652","title":"Kairos Pharma Signs Binding Deal to Acquire Worldwide Rights to CL-273","url":"https://stock-news.laohu8.com/highlight/detail?id=2616433652","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616433652?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:30","pubTimestamp":1772451023,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. said it has signed binding terms to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment. Kairos said CL-273 is an investigational, AI-designed, reversible, wild-type-sparing pan-EGFR inhibitor aimed at addressing resistance in EGFR-mutant non-small cell lung cancer, and that the deal is expected to be value-accretive. D. Boral Capital acted as sole financial advisor.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL7DfYcJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2616363563","title":"Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to Cl-273 From Orbimed and Torrey Pines Investment-Backed Celyn Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616363563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616363563?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:30","pubTimestamp":1772451000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA7CPH7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2616336545","title":"Kairos Pharma Ltd - to Buy Cl-273 From Celyn Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336545?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:30","pubTimestamp":1772451000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA7CPH7L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2614046044","title":"BRIEF-Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046044","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046044?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:23","pubTimestamp":1772108582,"startTime":"0","endTime":"0","summary":"BRIEF-Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset AcquisitionFeb 26 (Reuters) - Kairos Pharma Ltd KAPA.A:KAIROS PHARMA, LTD. ANNOUNCES SIGNING OF TERM SHEET FOR STRATEGIC ASSET A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA54JRGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2614045132","title":"Kairos Pharma signs term sheet to acquire CL-273 and CL-741 from Celyn Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045132","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045132?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:01","pubTimestamp":1772107284,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. signed a term sheet to acquire worldwide rights from Celyn Therapeutics to two clinical-stage oncology assets for non-small cell lung cancer: CL-273, a pre-IND reversible wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready oral type IIb c-MET inhibitor. The company said the proposed acquisition would expand its pipeline and support development of potential EGFR and MET combination therapy aimed at overcoming resistance in EGFR-mutant NSCLC.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL1gbj5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2614456530","title":"Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets From Celyn Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2614456530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614456530?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA54JRGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2614045669","title":"Kairos Pharma Ltd - to Buy Rights to Cl-273 and Cl-741","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045669?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA54JRGL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2604130681","title":"Kairos Pharma to Present at DealFlow Discovery Conference in Atlantic City","url":"https://stock-news.laohu8.com/highlight/detail?id=2604130681","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604130681?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:03","pubTimestamp":1768914221,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on January 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL2YMLd1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2603688444","title":"Kairos Pharma Ltd - May Offer up to $75 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2603688444","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603688444?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:01","pubTimestamp":1768302082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2584298239","title":"Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584298239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584298239?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:55","pubTimestamp":1763571322,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy maintained a Buy rating on Kairos Pharma, Ltd. yesterday and set a price target of $4.00. Jason McCarthy has giv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-clinical-developments-and-strategic-focus-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kairos-pharmas-promising-clinical-developments-and-strategic-focus-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2584411089","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2584411089","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584411089?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:19","pubTimestamp":1763558340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 08:19 ET (13:19 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2580375354","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580375354","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580375354?lang=en_us&edition=fundamental","pubTime":"2025-11-04 22:41","pubTimestamp":1762267260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 09:41 ET (14:41 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","KAIR"],"gpt_icon":0},{"id":"2580317247","title":"Kairos Pharma Secures Department of Defense Funding for ENV205 Cancer Drug Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2580317247","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580317247?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261232,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has announced the receipt of Department of Defense funding for research related to ENV205, a new drug aimed at treating chemotherapy drug resistance and cachexia. The funding supports the continued advancement of ENV205 as part of Kairos Pharma's broader focus on developing innovative cancer therapeutics. There is no indication that this grant was obtained by organizations other than Kairos Pharma Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL68SHx1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2580731962","title":"Kairos Pharma Provides Shareholder Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2580731962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580731962?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:00","pubTimestamp":1762261200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA90DLYR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2576059857","title":"Kairos Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2576059857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576059857?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:38","pubTimestamp":1760967480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KAPA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 09:38 ET (13:38 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAIR","KAPA"],"gpt_icon":0},{"id":"2576859939","title":"Kairos Pharma Reports Positive Phase 2 Results for ENV-105 in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2576859939","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576859939?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:01","pubTimestamp":1760961700,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has announced positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105  in patients with metastatic castration-resistant prostate cancer . The results were presented at the annual European Society Medical Oncologists  meeting in Berlin, Germany. The randomized trial, led by Dr. Edwin Posadas, is enrolling up to 100 patients across several cancer centers. Interim analysis showed that the combination of ENV-105 and apalutamide achieved a median progression-free survival of 13.7 months, with clinical benefit observed in 86% of treated patients. Seven out of nine evaluable patients experienced a reduction in PSA levels. ENV-105, a first-in-class CD105 antagonist, is being evaluated for its safety and efficacy in men with prostate cancer resistant to hormone therapy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDLfdr77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"gpt_icon":0},{"id":"2575229756","title":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575229756","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575229756?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:11","pubTimestamp":1760559083,"startTime":"0","endTime":"0","summary":"Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units  under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. publis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL96f3s8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"gpt_icon":0},{"id":"2574375975","title":"Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574375975","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574375975?lang=en_us&edition=fundamental","pubTime":"2025-10-09 01:05","pubTimestamp":1759943113,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on September 22. Jason McCarthy has given...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-developments-in-kairos-pharmas-lead-candidate-env-105-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-developments-in-kairos-pharmas-lead-candidate-env-105-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","KAPA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}